{
    "2020-07-12": [
        [
            {
                "time": "",
                "original_text": "【华西医药崔文亮团队】《康泰生物点评报告：疫情后接种恢复，推动业绩高速增长》",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "疫情后",
                        "接种恢复",
                        "业绩高速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|周报】板块跑赢大盘，坚守 CXO 和 API 领域",
                "features": {
                    "keywords": [
                        "民生医药",
                        "周报",
                        "板块跑赢大盘",
                        "CXO",
                        "API"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CXO",
                        "API"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}